CWP
QTTB icon

Clark Wealth Partners’s Q32 Bio QTTB Stock Holding History

Clark Wealth Partners’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-199
Closed -$297 – 650
2025
Q2 		$297 Hold
199
– – ﹤0.01% 502
2025
Q1 		$328 Hold
199
– – ﹤0.01% 498
2024
Q4 		$685 Buy
+199
New +$6.28K ﹤0.01% 474

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
TOCUITCONY
Trustees of Columbia University in the City of New York New York $891M AUM 17.3% 1-Year Est. Return

Clark Wealth Partners's QTTB Position: Q3 2025 in Review

Clark Wealth Partners sold out of Q32 Bio (QTTB) in Q3 2025, closing a stake of 199 shares — an estimated $297 sold.

Clark Wealth Partners first reported a position in QTTB in Q4 2024 and held it in 3 quarters. The position peaked at $685 in Q4 2024. 53 funds tracked by Wall St. Rank hold QTTB as of Q3 2025.

  • Clark Wealth Partners reported no remaining Q32 Bio position as of Q3 2025 after selling out during the quarter.
  • Clark Wealth Partners sold 199 Q32 Bio shares in Q3 2025, an estimated $297.
  • Clark Wealth Partners first reported a position in Q32 Bio in Q4 2024 and held it in 3 quarters.
  • Clark Wealth Partners's Q32 Bio position peaked at $685 in Q4 2024.
  • 53 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2025.

Based on Clark Wealth Partners's 13F filing for Q3 2025, filed 4 Feb 2026.